



Post Authorisation Assessments

Vetoryl 30 mg Hard Capsules Vm 10434/5008

•	08 February 2023	Deletion of a non-significant in-process test during the manufacture of the finished product.
•	23 January 2023	Editorial changes to part 2 of the dossier.
•	07 September 2022	Deletion of a non-significant in-process test during the manufacture of the finished product.
•	28 July 2022	Editorial changes to Part II B of the dossier for the 10 mg hard capsules. Editorial changes to Part II C of the dossier for the 5 mg and 60 mg hard capsules. Editorial changes to Part II F of the dossier for the 30 mg, 60 mg and 120 mg hard capsules.
•	29 March 2022	Deletion of a non-significant in-process test applied during the manufacture of the finished product.
•	16 November 2021	Addition of a new specification parameter to the specification with its corresponding test method of the finished product.
•	23 September 2021	Addition of a primary packaging site of the finished product. Addition of a secondary packaging site of the finished product.
•	09 February 2021	Submission of an updated Ph. Eur. TSE certificate of suitability for a starting material from an already approved manufacturer.
•	21 April 2020	Deletion of manufacturing site where batch control takes place.
•	17 October 2019	Submission of an updated Ph. Eur. TSE certificate of suitability for a starting material from an already approved manufacturer. Submission of a new Ph. Eur. TSE certificate of suitability from a new / already approved manufacturer. Deletion of Ph. Eur. TSE certificates of suitability. Submission of an updated Ph. Eur. TSE certificate of suitability for a starting material from an already approved manufacturer.
•	24 September 2019	Changes to a test procedure for the finished product
•	07 August 2019	Update to the ASMF.
•	18 June 2019	Addition of a manufacturer responsible for batch release including batch control/testing.
•	02 April 2019	Minor change to an approved test procedure for the active substance.
•	12 February 2019	Changes to an existing pharmacovigilance system as described in the DDPS.
•	08 February 2019	Introduction of a new site of manufacture
•	01 August 2018	Change in RMS from UK to IE.
•	19 December 2017	Repeat Use application to add 2 new member states.
•	02 February 2017	Changes to the labelling and package leaflet.
•	17 May 2016	Deletion of a TSE certificate.

		Submission of a new TSE certificate. Submission of an updated TSE certificate. Submission of a new TSE certificate. Submission of a new TSE certificate.
•	25 November 2015	Additional site for batch testing of the finished product.
•	21 May 2015	Submission of updated Ph. Eur. Certificates of Suitability from an already approved manufacturer
•	20 November 2014	Updates to the labelling and package leaflet.
•	10 October 2014	Change of MA holder address.
•	06 March 2014	Significant change to the SPC with regard to clinical data.
•	14 November 2013	Grouped variation concerning changes to the manufacturing process, test procedures, and the manufacturer of the active substance.
•	03 May 2012	Submission of a new Ph. Eur. Certificate of Suitability.
•	02 March 2012	Change in the manufacturer of the active substance.
•	09 December 2011	To change the ink used to mark the capsules.
•	01 April 2011	Changes to an existing pharmacovigilance system as described in the DDPS.
•	15 December 2010	Change of Distributor.
•	06 October 2010	To change the Marketing Authorisation Holder.
•	17 September 2010	Change in immediate packaging of the finished product.
•	17 September 2010	Submission of new or updated Ph. Eur Certificates of Suitability.
•	17 September 2010	Submission of new or updated Ph. Eur Certificates of Suitability.
•	17 September 2010	Submission of new or updated Ph. Eur Certificates of Suitability.
•	17 September 2010	Submission of new or updated Ph. Eur Certificates of Suitability.
•	17 September 2010	Submission of new or updated Ph. Eur Certificates of Suitability.
•	17 September 2010	Submission of new or updated Ph. Eur Certificates of Suitability.
•	17 September 2010	Submission of new or updated Ph. Eur Certificates of Suitability.
•	23 October 2008	Change shelf life of finished product (as packaged for sale).
•	03 October 2008	Change active/intermediate batch size.
•	21 November 2007	Variation to endorse manufacturing process.
•	05 July 2007	Change test procedure for active/active component.
•	01 June 2007	Change finished product test procedure.
•	01 June 2007	Change finished product test procedure.
•	16 May 2007	Change/addition of imprints/bossing/markings on tabs or capsules.
•	16 May 2007	Change in batch size of finished product.
•	16 May 2007	Change to batch release arrangements.
•	08 March 2006	Change of distributor.
•	15 February 2006	Replace/add manufacturing site.
•	18 March 2005	Change in specifications of active substance.